The new landscape of therapy for myelofibrosis

Current Hematologic Malignancy Reports

Volumn 8, Issue 4, 2013, Pages 325-332

  Gowin, Krisstina ^a   Emanuel, Robyn ^a   Geyer, Holly ^a   Mesa, Ruben A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Hematologic malignancy; JAK2 inhibitors; Myelofibrosis; Myeloproliferative neoplasms; Ruxolitinib

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; ANDROGEN; ANTIANEMIC AGENT; BMS 911543; CORTICOSTEROID; EVEROLIMUS; FEDRATINIB; GANDOTINIB; GIVINOSTAT; GRN 163; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; IMMUNOMODULATING AGENT; INCB 39110; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; LENALIDOMIDE; LESTAURTINIB; MOMELOTINIB; NS 018; PACRITINIB; PANOBINOSTAT; PHENYLALANINE; PLACEBO; POMALIDOMIDE; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; RUXOLITINIB; SARIDEGIB; SIMTUZUMAB; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALINE; XL 019;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; AMINO ACID SUBSTITUTION; ANEMIA; ARTICLE; BLOOD CELL COUNT; BONE MARROW; CLINICAL TRIAL (TOPIC); COMORBIDITY; CORTICOSTEROID THERAPY; CYTOPENIA; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ENZYME INHIBITION; EUROPE; FATIGUE; GASTROINTESTINAL TOXICITY; GENE MUTATION; HISTOPATHOLOGY; HUMAN; LEUKOPENIA; MORBIDITY; MORTALITY; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; NEUROLOGIC DISEASE; NEUTROPENIA; PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SPLENECTOMY; SPLENOMEGALY; SURVIVAL RATE; SYMPTOMATOLOGY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UNITED STATES;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HEMATOLOGIC NEOPLASMS; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNOLOGIC FACTORS; JANUS KINASES; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; PYRAZOLES;

EID: 84890501821     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-013-0178-x     Document Type: Article

References (51)

1. Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, Dupriez B et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res. 2007.
2. James C, Ugo V, Casadevall N, Constantinescu SN, Vainchenker W. A JAK2 mutation in myeloproliferative disorders: Pathogenesis and therapeutic and scientific prospects. Trends Mol Med. 2005;11(12):546-54. The first description of JAK2-V617F in MPNs, a watershed both in therapeutic targeting and well as pathogenetic insight.
3. Kralovics R, Passamonti F, Buser AS, Soon-Siong T, Tiedt R, Passweg JR, et al. A gain of function mutation in Jak2 is frequently found in patients with myeloproliferative disorders. New Engl J Med. 2005;352:1779-90.
4. Abdel-Wahab O, Tefferi A, Levine RL. Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms. Hematol Oncol Clin North Am. 2012;26(5):1053-64. doi: 10.1016/j.hoc.2012.07.006.
5. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289-301. doi: 10.1056/NEJMoa0810069.
6. Oh ST, Simonds EF, Jones C, Hale MB, Goltsev Y, Gibbs Jr KD, et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood. 2010;116(6):988-92. doi: 10.1182/blood-2010-02-270108.
7. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270.
8. Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer. 2012;12(9):599-612. doi: 10.1038/nrc3343.
9. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010;24(6):1128-38. doi: 10.1038/leu.2010.69.
10. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011;118(7):1723-35. doi: 10.1182/blood-2011-02-292102.
11. Zhang SJ, Abdel-Wahab O. Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms. Curr Hematol Malig Rep. 2012;7(1):34-42. doi: 10.1007/s11899-011-0105-y.
12. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009. doi: 10.1182/blood-2009-03-209262.
13. Mesa RA, Shields A, Hare T, Erickson-Viitanen S, Sun W, Sarlis NJ, et al. Progressive burden of myelofibrosis in untreated patients: Assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study. Leuk Res. 2013. doi: 10.1016/j.leukres.2013.04.017.
14. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-901. doi: 10.1182/blood-2008-07-170449.
15. Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: Prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30(33):4098-103. doi: 10.1200/JCO.2012.42.3863.
16. Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, et al. Thrombosis in primary myelofibrosis: Incidence and risk factors. Blood. 2010;115(4):778-82. doi: 10.1182/blood-2009-08-238956.
17. Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, et al. The myeloproliferative neoplasm symptom assessment form (MPN-SAF): International prospective validation and reliability trial in 402 patients. Blood. 2011;118(2):401-8. doi: 10.1182/blood-2011-01-328955.
18. Geyer HL, Dueck AC, Emanuel RM, Kiladjian J-J, Slot S, Zweegman S, et al. The myelofibrosis symptom burden (MF-SB): An international phenotypic cluster analysis of 329 patients. ASH Annual Meeting Abstracts. 2012;120(21):1731.
19. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703-8. doi: 10.1182/blood-2009-09-245837.
20. Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, et al. DIPSS plus: A refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392-7.
21. Mesa RA. The evolving treatment paradigm in myelofibrosis. Leuk Lymphoma. 2013;54(2):242-51. doi: 10.3109/10428194.2012.710905.
22. Kroger N, Holler E, Kobbe G, Bornhauser M, Schwerdtfeger R, Baurmann H, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the chronic leukemia working party of the European group for blood and marrow transplantation. Blood. 2009;114(26):5264-70. doi: 10.1182/blood-2009-07-234880.
23. Fauble V, Leis J, Mesa R. Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors. Leukemia. 2012(Supplement 2012):S2-S7
24. Cervantes F, Alvarez-Larran A, Domingo A, Arellano-Rodrigo E, Montserrat E. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: Long-term results in 30 patients. Br J Haematol. 2005;129(6):771-5.
25. Tsiara SN, Chaidos A, Bourantas LK, Kapsali HD, Bourantas KL. Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis. Acta Haematol. 2007;117(3):156-61. doi: 10.1159/000097463.
26. Huang J, Tefferi A. Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level. Eur J Haematol. 2009;83(2):154-5. doi: 10.1111/j.1600-0609.2009.01266.x.
27. Thapaliya P, Tefferi A, Pardanani A, Steensma DP, Camoriano J, Wu W, et al. International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens. Am J Hematol. 2011;86(1):96-8. doi: 10.1002/ajh.21892.
28. Martinez-Trillos A, Gaya A, Maffioli M, Arellano-Rodrigo E, Calvo X, Diaz-Beya M, et al. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: Results in 40 patients. Ann Hematol. 2010;89(12):1233-7.
29. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-98. doi: 10.1056/NEJMoa1110556. First randomized phase III trial of a JAK2 inhibitor vs. best available therapy in myelofibrosis.
30. Faoro L, Mesa R, Gertz MA, Tefferi A. Long-term analysis of the palliative benefit of 2-Chlorodeoxyadenosine (2-CdA) for myelofibrosis with myeloid metaplasia. Am J Clin Oncol. 2004.
31. Mesa RA, Nagorney DS, Schwager S, Allred J, Tefferi A. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer. 2006;107(2):361-70.
32. Elliott MA, Chen MG, Silverstein MN, Tefferi A. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol. 1998;103(2):505-11.
33. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis. New Engl J Med. 2010;363(12):1117-27. doi: 10.1056/NEJMoa1002028.
34. Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: Survival advantage in comparison to matched historical controls. Blood. 2012;120(6):1202-9. doi: 10.1182/blood-2012-02-414631.
35. Kvasnicka H-M, Thiele J, Bueso-Ramos CE, Hou K, Cortes JE, Kantarjian HM. Exploratory analysis of the effect of ruxolitinib on bone marrow morphology in patients with myelofibrosis. J Clin Oncol. 2013;31:7030.
36. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807. doi: 10.1056/NEJMoa1110557. First randomized trial of JAK2 inhibitor vs. placebo, demonstrating a survival advantage in myelofibrosis.
37. Mesa RA, Gotlib J, Gupta V, Catalano JV, Deininger MW, Shields AL, et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2013;31(10):1285-92. doi: 10.1200/JCO.2012.44.4489.
38. Harrison CN, Mesa RA, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, et al. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. Br J Haematol. 2013. doi: 10.1111/bjh.12375.
39. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. Br J Haematol. 2013;161(4):508-16. doi: 10.1111/bjh.12274.
40. Vannucchi A, Cervantes F, Niederwieser D, Sirulnik A, Stalbovskaya V, McQuitty M et al. Long-term outcomes from a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF): A 3-YEAR update of COMFORT-II. Haematologica. 2013; Suppl:a5828.
41. Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011;29(7):789-96.
42. Animesh Dev Pardanani CHMJ, Gabrail NY, et al. Updated results from a randomized phase II dose-ranging study of the JAK2-selective inhibitor SAR302503 in patients with myelofibrosis (MF). J Clin Oncol. 2013;31:7109.
43. Deeg HJOO, Scott BL, et al. Phase II study of SB1518, an orally available novel Jak2 inhibitor, in patients with myelofibrosis. J Clin Oncol. 2011;29:6515.
44. Komrokji RS, Wadleigh M, Seymour JF, Roberts AW, To LB, Zhu HJ, et al. Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis. ASH Ann Meet Abs. 2011;118(21):282.
45. Pardanani A, Laborde RR, Lasho TL, Finke C, Begna K, Al-Kali A, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 2013;27(6):1322-7. doi: 10.1038/leu.2013.71.
46. Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H et al. Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis. J Clin Oncol. 2009.
47. Mesa RA, Pardanani AD, Hussein K, Wu W, Schwager S, Litzow MR, et al. Phase1/-2 study of Pomalidomide in myelofibrosis. Am J Hematol. 2010;85(2):129-30. doi: 10.1002/ajh.21598.
48. Deangelo DJ, Mesa RA, Fiskus W, Tefferi A, Paley C, Wadleigh M, et al. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis. Br J Haematol. 2013. doi: 10.1111/bjh.12384.
49. Rambaldi A, Dellacasa CM, Finazzi G, Carobbio A, Ferrari ML, Guglielmelli P, et al. A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol. 2010;150(4):446-55. doi: 10.1111/j.1365-2141.2010.08266.x.
50. Guglielmelli P, Barosi G, Rambaldi A, Marchioli R, Masciulli A, Tozzi L, et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood. 2011;118(8):2069-76. doi: 10.1182/blood-2011-01-330563.
51. Constantinescu SN, Vainchenker W. Small-molecule inhibitors in myeloproliferative neoplasms: Are we aiming for the right targets? Hematol Am Soc Hematol Educ Program. 2012;2012:553-60. doi: 10.1182/asheducation-2012.1. 553.